Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

BACKGROUND: Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy u...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Victor H. F., Leung, Dennis K. C., Choy, Tim-Shing, Lam, Ka-On, Lam, Pui-Mei, Leung, To-Wai, Kwong, Dora L. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765101/
https://www.ncbi.nlm.nih.gov/pubmed/26911310
http://dx.doi.org/10.1186/s12885-016-2201-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765101/
https://www.ncbi.nlm.nih.gov/pubmed/26911310
http://dx.doi.org/10.1186/s12885-016-2201-9

Ejemplares similares